These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 25739551)
1. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Seo AN; Kwak Y; Kim WH; Kim DW; Kang SB; Choe G; Lee HS Virchows Arch; 2015 Jun; 466(6):645-54. PubMed ID: 25739551 [TBL] [Abstract][Full Text] [Related]
2. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Lédel F; Hallström M; Ragnhammar P; Öhrling K; Edler D Eur J Cancer; 2014 Feb; 50(3):656-62. PubMed ID: 24300455 [TBL] [Abstract][Full Text] [Related]
3. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189 [TBL] [Abstract][Full Text] [Related]
4. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854 [TBL] [Abstract][Full Text] [Related]
5. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. Cao GD; Chen K; Chen B; Xiong MM BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126 [TBL] [Abstract][Full Text] [Related]
6. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH. Buhmeida A; Assidi M; Al-Maghrabi J; Dallol A; Sibiany A; Al-Ahwal M; Chaudhary A; Abuzenadah A; Al-Qahtani M Cancer Invest; 2018 Feb; 36(2):129-140. PubMed ID: 29504811 [TBL] [Abstract][Full Text] [Related]
8. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122 [TBL] [Abstract][Full Text] [Related]
9. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients. Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients. Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357 [TBL] [Abstract][Full Text] [Related]
11. HER3 expression is correlated to distally located and low-grade colon cancer. Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D Acta Oncol; 2016 Jul; 55(7):875-80. PubMed ID: 26863446 [TBL] [Abstract][Full Text] [Related]
12. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313 [TBL] [Abstract][Full Text] [Related]
13. EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosis. Brunner K; Fischer CA; Driemel O; Hartmann A; Brockhoff G; Schwarz S Anal Quant Cytol Histol; 2010 Apr; 32(2):78-89. PubMed ID: 20701076 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer. Dębska-Szmich S; Kusińska R; Czernek U; Szydłowska-Pazera K; Habib-Lisik M; Piekarski JH; Olas E; Kulig A; Ułańska M; Kalinka-Warzocha E; Potemski P Postepy Hig Med Dosw (Online); 2015 May; 69():586-97. PubMed ID: 25983297 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. Chung YW; Kim S; Hong JH; Lee JK; Lee NW; Lee YS; Song JY J Gynecol Oncol; 2019 Sep; 30(5):e75. PubMed ID: 31328457 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
17. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre. Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345 [TBL] [Abstract][Full Text] [Related]
18. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. Zhang XL; Yang YS; Xu DP; Qu JH; Guo MZ; Gong Y; Huang J World J Surg; 2009 Oct; 33(10):2112-8. PubMed ID: 19636613 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis. Pyo JS; Kang G; Park K Int J Biol Markers; 2016 Dec; 31(4):e389-e394. PubMed ID: 27102863 [TBL] [Abstract][Full Text] [Related]
20. HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]